Payment overview · 2025
General Payments
$2,751.82
144 reported records · 30 companies
Healthcare provider profile · identity verified
Jonathan Patrick Mcfadden, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WESTERVILLE, OH · NPI 1083057418
Verified facts
What the public records show
CMS Open Payments records show Jonathan Patrick Mcfadden, DO received $2,751.82 in general payments during 2025 across 144 reported records.
Novo Nordisk Inc accounted for 14.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Shingrix, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $384.57 | 14.0% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $275.16 | 10.0% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $239.69 | 8.7% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $198.86 | 7.2% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $193.10 | 7.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.67 | 6.2% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $140.33 | 5.1% | 8 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $114.25 | 4.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $103.86 | 3.8% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $97.45 | 3.5% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $87.25 | 3.2% | 5 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $76.39 | 2.8% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $70.00 | 2.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $68.60 | 2.5% | 4 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $64.79 | 2.4% | 3 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $61.50 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.11 | 2.1% | 3 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $48.29 | 1.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.02 | 1.7% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$45.46 | 1.6% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $34.12 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.66 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.37 | 1.0% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $21.70 | 0.8% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $20.02 | 0.7% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $19.17 | 0.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $15.01 | 0.6% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.77 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.36 | 0.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.29 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,687.28 | 142 |
| Education | $64.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $254.31 | 14 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $223.01 | 12 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $193.10 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $176.55 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $171.23 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $154.11 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $153.44 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $119.49 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $116.36 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $111.79 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $108.53 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $100.82 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $97.45 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $90.30 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $87.25 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $85.66 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $79.71 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.71 | 5 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $76.39 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $70.00 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $69.75 | 4 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $68.60 | 4 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $64.79 | 3 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $64.79 | 3 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $61.50 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $48.29 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.02 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.02 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $39.51 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $34.12 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $34.12 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $33.38 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $27.66 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.27 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.27 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $12.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 102 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 30 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 448 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 55 |
| Losartan Potassium | Losartan Potassium | 203 | 50 |
| Omeprazole | Omeprazole | 159 | 43 |
| Lisinopril | Lisinopril | 143 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 39 |
| Carvedilol | Carvedilol | 103 | 25 |
| Eliquis | Apixaban | 102 | 28 |
| Gabapentin | Gabapentin | 97 | 22 |
| Metformin Hcl Er | Metformin Hcl | 97 | 20 |
| Jardiance | Empagliflozin | 88 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 24 |
| Metformin Hcl | Metformin Hcl | 74 | 18 |
| Ezetimibe | Ezetimibe | 72 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 21 |
| Furosemide | Furosemide | 70 | 21 |
| Ozempic | Semaglutide | 70 | 12 |
| Sertraline Hcl | Sertraline Hcl | 62 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 18 |
| Allopurinol | Allopurinol | 58 | 17 |
| Bupropion Xl | Bupropion Hcl | 56 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 14 |
| Meloxicam | Meloxicam | 53 | 18 |
| Prednisone | Prednisone | 52 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 24 |
| Trazodone Hcl | Trazodone Hcl | 48 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 15 |
| Montelukast Sodium | Montelukast Sodium | 44 | 11 |
| Atenolol | Atenolol | 43 | 11 |
| Potassium Chloride | Potassium Chloride | 43 | 16 |
| Simvastatin | Simvastatin | 42 | suppressed |
| Glimepiride | Glimepiride | 41 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Finasteride | Finasteride | 36 | 11 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 23 |
| Azithromycin | Azithromycin | 29 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Probenecid | Probenecid | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,751.82 · 144 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, BodyGuardian, CAMZYOS, COMIRNATY, CREON, CeQur Simplicity, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INCEPTIV, ISTURISA, JARDIANCE, KRYSTEXXA, LEQVIO, LINZESS, MOUNJARO, NEFFY, NEXLETOL, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, RECORLEV, REPATHA, Rybelsus, SHINGRIX, SYNTHROID, TWIIST, TZIELD, Tymlos, UBRELVY, UNITHROID, UPTRAVI, VOQUEZNA, VRAYLAR, Wegovy, Yorvipath, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error